Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
46
PPTDF Quote, Financials, Valuation and Earnings
Last price:
$10.95
Seasonality move
:
4.8%
Day range:
$10.95 - $10.95
52-week range:
$9.61 - $17.85
Dividend yield:
0%
P/E ratio:
13.79x
P/S ratio:
11.79x
P/B ratio:
3.97x
Volume:
--
Avg. volume:
73
1-year change:
-35.62%
Market cap:
$1.4B
Revenue:
$308.1M
EPS (TTM):
-$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
AMGXF
AnGes, Inc.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | -1.44% | -- | $17.76 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PPTDF
PeptiDream Inc.
|
$10.95 | -- | $1.4B | 13.79x | $0.00 | 0% | 11.79x |
|
AMGXF
AnGes, Inc.
|
$0.36 | -- | $139.1M | -- | $0.00 | 0% | 21.61x |
|
HLOSF
Healios KK
|
$3.40 | -- | $392.4M | -- | $0.00 | 0% | 533.86x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.00 | -- | $452.5M | -- | $0.00 | 0% | 2.34x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.31 | $17.76 | $45.2B | 181.60x | $0.34 | 4.65% | 1.54x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
AMGXF
AnGes, Inc.
|
3.92% | 0.348 | 0.83% | 1.55x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.605 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
AMGXF
AnGes, Inc.
|
$669.9K | -$7.7M | -326.92% | -349.76% | -494.08% | -- |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
PeptiDream Inc. vs. Competitors
-
Which has Higher Returns PPTDF or AMGXF?
AnGes, Inc. has a net margin of -25.38% compared to PeptiDream Inc.'s net margin of -312.66%. PeptiDream Inc.'s return on equity of -10.42% beat AnGes, Inc.'s return on equity of -349.76%.
Company Gross Margin Earnings Per Share Invested Capital PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M AMGXFAnGes, Inc.42.74% -$0.01 $29.4M -
What do Analysts Say About PPTDF or AMGXF?
PeptiDream Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that PeptiDream Inc. has higher upside potential than AnGes, Inc., analysts believe PeptiDream Inc. is more attractive than AnGes, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PPTDFPeptiDream Inc.0 0 0 AMGXFAnGes, Inc.0 0 0 -
Is PPTDF or AMGXF More Risky?
PeptiDream Inc. has a beta of 0.569, which suggesting that the stock is 43.146% less volatile than S&P 500. In comparison AnGes, Inc. has a beta of 0.060, suggesting its less volatile than the S&P 500 by 94.03%.
-
Which is a Better Dividend Stock PPTDF or AMGXF?
PeptiDream Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnGes, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PeptiDream Inc. pays -- of its earnings as a dividend. AnGes, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPTDF or AMGXF?
PeptiDream Inc. quarterly revenues are $29.3M, which are larger than AnGes, Inc. quarterly revenues of $1.6M. PeptiDream Inc.'s net income of -$7.4M is lower than AnGes, Inc.'s net income of -$4.9M. Notably, PeptiDream Inc.'s price-to-earnings ratio is 13.79x while AnGes, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PeptiDream Inc. is 11.79x versus 21.61x for AnGes, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPTDFPeptiDream Inc.11.79x 13.79x $29.3M -$7.4M AMGXFAnGes, Inc.21.61x -- $1.6M -$4.9M
-
Which has Higher Returns PPTDF or HLOSF?
Healios KK has a net margin of -25.38% compared to PeptiDream Inc.'s net margin of -9751.87%. PeptiDream Inc.'s return on equity of -10.42% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About PPTDF or HLOSF?
PeptiDream Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that PeptiDream Inc. has higher upside potential than Healios KK, analysts believe PeptiDream Inc. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings PPTDFPeptiDream Inc.0 0 0 HLOSFHealios KK0 0 0 -
Is PPTDF or HLOSF More Risky?
PeptiDream Inc. has a beta of 0.569, which suggesting that the stock is 43.146% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock PPTDF or HLOSF?
PeptiDream Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PeptiDream Inc. pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPTDF or HLOSF?
PeptiDream Inc. quarterly revenues are $29.3M, which are larger than Healios KK quarterly revenues of $128.8K. PeptiDream Inc.'s net income of -$7.4M is lower than Healios KK's net income of $3.8M. Notably, PeptiDream Inc.'s price-to-earnings ratio is 13.79x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PeptiDream Inc. is 11.79x versus 533.86x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPTDFPeptiDream Inc.11.79x 13.79x $29.3M -$7.4M HLOSFHealios KK533.86x -- $128.8K $3.8M
-
Which has Higher Returns PPTDF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of -25.38% compared to PeptiDream Inc.'s net margin of -24.76%. PeptiDream Inc.'s return on equity of -10.42% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About PPTDF or SOLTF?
PeptiDream Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that PeptiDream Inc. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe PeptiDream Inc. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PPTDFPeptiDream Inc.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is PPTDF or SOLTF More Risky?
PeptiDream Inc. has a beta of 0.569, which suggesting that the stock is 43.146% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock PPTDF or SOLTF?
PeptiDream Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PeptiDream Inc. pays -- of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPTDF or SOLTF?
PeptiDream Inc. quarterly revenues are $29.3M, which are smaller than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. PeptiDream Inc.'s net income of -$7.4M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, PeptiDream Inc.'s price-to-earnings ratio is 13.79x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PeptiDream Inc. is 11.79x versus 2.34x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPTDFPeptiDream Inc.11.79x 13.79x $29.3M -$7.4M SOLTFNxera Pharma Co., Ltd.2.34x -- $45.8M -$11.3M
-
Which has Higher Returns PPTDF or STMM?
Stemcell Holdings, Inc. has a net margin of -25.38% compared to PeptiDream Inc.'s net margin of --. PeptiDream Inc.'s return on equity of -10.42% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About PPTDF or STMM?
PeptiDream Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that PeptiDream Inc. has higher upside potential than Stemcell Holdings, Inc., analysts believe PeptiDream Inc. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PPTDFPeptiDream Inc.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is PPTDF or STMM More Risky?
PeptiDream Inc. has a beta of 0.569, which suggesting that the stock is 43.146% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PPTDF or STMM?
PeptiDream Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PeptiDream Inc. pays -- of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PPTDF or STMM?
PeptiDream Inc. quarterly revenues are $29.3M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. PeptiDream Inc.'s net income of -$7.4M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, PeptiDream Inc.'s price-to-earnings ratio is 13.79x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PeptiDream Inc. is 11.79x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPTDFPeptiDream Inc.11.79x 13.79x $29.3M -$7.4M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns PPTDF or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of -25.38% compared to PeptiDream Inc.'s net margin of -1.05%. PeptiDream Inc.'s return on equity of -10.42% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About PPTDF or TAK?
PeptiDream Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.76 which suggests that it could grow by 23.91%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings PPTDFPeptiDream Inc.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is PPTDF or TAK More Risky?
PeptiDream Inc. has a beta of 0.569, which suggesting that the stock is 43.146% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.027, suggesting its less volatile than the S&P 500 by 97.262%.
-
Which is a Better Dividend Stock PPTDF or TAK?
PeptiDream Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.65% to investors and pays a quarterly dividend of $0.34 per share. PeptiDream Inc. pays -- of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend.
-
Which has Better Financial Ratios PPTDF or TAK?
PeptiDream Inc. quarterly revenues are $29.3M, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. PeptiDream Inc.'s net income of -$7.4M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, PeptiDream Inc.'s price-to-earnings ratio is 13.79x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 181.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PeptiDream Inc. is 11.79x versus 1.54x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PPTDFPeptiDream Inc.11.79x 13.79x $29.3M -$7.4M TAKTakeda Pharmaceutical Co., Ltd.1.54x 181.60x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 5
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
